In the long human effort to catch illness before it takes hold, a urine test developed at the University of Birmingham and trialled across NHS hospitals in England and Scotland has shown it can identify more than nine in ten cases of bladder cancer — offering patients a gentler first step in a diagnostic journey that has long begun with an invasive camera procedure. The Galeas test, which reads genetic signals shed by cancer cells into urine, does not replace the cystoscope, but it may reshape who reaches it first and how urgently. At a moment when waiting lists stretch and discomfort is a bar
NHS-trialled urine test detects over 90% of bladder cancers
A negative result meant there was more than a 99% chance the patient did not have bladder cancer.
Mark
So this test works by looking for cancer DNA in urine—how does that actually translate to a 92% detection rate? Is that good?
Mimi
It's quite strong for a screening tool. The test scans for over 450 mutations across 23 genes that are known to be present in bladder cancer cells. When cancer is there, those cells shed genetic material into the urine. The 92% means it caught nine out of every ten cases in the trial.
Luke
But we should be clear: this trial involved nearly 1,000 patients at seven hospitals. That's a real-world sample, but it's not yet a massive population study. And 92% means one in ten cases were missed. For some cancers, that gap matters.
Mimi
True. That's why it's not replacing cystoscopy—it's meant to triage. If you test negative, there's a 99% chance you don't have cancer, so you can skip the invasive procedure. If you test positive, you still get the camera procedure to confirm.
Mark
And the waiting lists are the real problem here, right? Over 300,000 cystoscopies a year in the UK.
Mimi
Exactly. In some areas, people wait months. This test could let doctors fast-track the high-risk patients and reassure the low-risk ones without making them wait for a procedure.
Luke
The source says "if a larger trial is successful, it could mean tens of thousands of patients a year are spared these tests." That's a projection, not a guarantee. We don't know yet what the larger trial will show.
Mark
So what's the timeline?
Mimi
The study is published now, but there's no date given for the next phase. It's early days.
Luke
And it's worth noting: the test was developed with public funding from Cancer Research UK, but it's now commercialised by Nonacus. They pay back revenue to the university and the charity, but there's a commercial interest here.
Mimi
That's fair to flag. But the science came from academia first, and the trial was NHS-run. The commercialisation is how it gets to patients.
Mark
If this works out, how many people could actually benefit?
Mimi
Potentially tens of thousands per year, according to the researchers. But that assumes the larger trial succeeds and the NHS decides to roll it out widely.
O Pulso
- Over 300,000 cystoscopies are performed in the UK each year, and the waiting lists behind them mean that for many patients, the path to a bladder cancer diagnosis is slow, uncomfortable, and uncertain.
- The Galeas urine test — scanning more than 450 DNA mutations across 23 genes — correctly identified 92% of bladder cancer cases and returned a greater than 99% probability of no cancer when results were negative.
- A trial of nearly 1,000 patients across seven hospitals has given researchers their first substantial real-world evidence that the test performs outside the laboratory, a critical threshold in the journey toward clinical adoption.
- The test is not designed to replace the cystoscope but to act as a triage filter, fast-tracking high-risk patients while sparing those with negative results from procedures they may not need.
- Researchers and Cancer Research UK both caution that larger trials are still required, but estimate that tens of thousands of patients per year could eventually avoid invasive diagnostic procedures if the evidence holds.
In the long human effort to catch illness before it takes hold, a urine test developed at the University of Birmingham and trialled across NHS hospitals in England and Scotland has shown it can identify more than nine in ten cases of bladder cancer — offering patients a gentler first step in a diagnostic journey that has long begun with an invasive camera procedure. The Galeas test, which reads genetic signals shed by cancer cells into urine, does not replace the cystoscope, but it may reshape who reaches it first and how urgently. At a moment when waiting lists stretch and discomfort is a barrier to timely care, this small act of detection at home carries the weight of a much larger question: how much suffering in medicine is diagnostic, and how much of it might one day be spared.
A urine test performed at home has shown it can detect more than nine in ten bladder cancer cases, according to findings from an NHS trial published in European Urology Oncology. Developed by researchers at the University of Birmingham with Cancer Research UK funding and commercialised by diagnostics company Nonacus, the Galeas test was evaluated across nearly 1,000 patients at seven hospitals in England and Scotland — a meaningful step beyond the laboratory.
The test works by identifying genetic material that bladder cancer cells shed into urine, scanning for over 450 DNA mutations across 23 genes. In the trial it detected 92% of cancers, and when results came back negative, they indicated a greater than 99% probability that cancer was absent. That combination of sensitivity and reassurance matters in a system where more than 300,000 cystoscopies — invasive camera examinations of the bladder — are performed each year, often after considerable waiting.
Researchers are clear that Galeas is not a replacement for cystoscopy, which remains the definitive diagnostic tool. Instead, it could serve as a filter: directing the highest-risk patients toward urgent procedures while sparing those with negative results from an uncomfortable wait. If a larger trial confirms these findings, tens of thousands of patients per year could avoid invasive testing altogether.
Professor Richard Bryan, who co-authored the study, described the results as exciting after years of development. Cancer Research UK's Michelle Mitchell welcomed the direction while noting that further research is needed, pointing to the real cost of delayed diagnosis for patients who currently wait longer than necessary. Bladder cancer, most common in men over 60 and often first signalled by blood in the urine, responds far better to early detection — making a faster, less burdensome diagnostic pathway not merely convenient, but potentially life-saving.
A simple urine test performed at home has shown it can catch more than nine in ten cases of bladder cancer, according to findings from an NHS trial now published in European Urology Oncology. The test, called Galeas, was developed by researchers at the University of Birmingham with funding from Cancer Research UK, then commercialised by the diagnostics company Nonacus. The trial involved nearly 1,000 patients across seven hospitals in England and Scotland, making it a substantial real-world evaluation of how the test performs outside the laboratory.
The appeal of this test lies partly in what it might spare patients from enduring. Each year in the UK, more than 300,000 cystoscopies are performed—procedures in which doctors insert a small camera up the urethra and into the bladder to look for cancer. These are invasive, uncomfortable, and in many parts of the country, patients face significant waiting lists to have one done. The Galeas test works by detecting genetic material that bladder cancer cells shed into urine, specifically looking for more than 450 DNA mutations across 23 genes associated with the disease. When the test came back negative, it indicated a greater than 99% probability that the patient did not have bladder cancer.
In the trial, the test identified 92% of bladder cancer cases. Researchers are careful to note that this is not a replacement for cystoscopy—the camera procedure remains the definitive diagnostic tool. Rather, the urine test could serve as a filter, helping doctors identify which patients are at highest risk and should be prioritised for urgent cystoscopy, while those with negative results can be reassured and spared the procedure or placed lower on waiting lists. If a larger trial proves successful, the researchers estimate that tens of thousands of patients per year could avoid these invasive tests altogether.
Professor Richard Bryan from Birmingham University, who co-authored the study, described the moment of seeing the test perform well in a large patient population as exciting, after years spent developing and refining the underlying science. Michelle Mitchell from Cancer Research UK acknowledged that while the test is still in early stages and further research is needed, the direction is encouraging. She noted that too many people currently wait longer than necessary for a bladder cancer diagnosis, and finding faster, less invasive ways to detect or rule out the disease is essential.
Bladder cancer is more common in men over 60, and blood in the urine is typically the first sign. How serious the disease becomes depends on the size of the tumour and whether it has spread beyond the bladder. Early detection and prompt treatment improve survival significantly. The Galeas test represents one potential tool in that effort—not a cure, not a replacement for existing procedures, but a way to make the diagnostic pathway faster and less burdensome for patients. The next step is a larger trial; if that succeeds, the NHS may eventually offer this test more widely, reshaping how bladder cancer is screened and diagnosed across the country.
Citações Notáveis
After years developing and evaluating the science, it was exciting to see very promising early performance in a large real-world patient population.— Professor Richard Bryan, University of Birmingham
Too many people are waiting longer than they should for a bladder cancer diagnosis, and it's essential that we find ways to tackle this problem.— Michelle Mitchell, Cancer Research UK
Quer a matéria completa?
Leia o original em BBC News ↗
Business